Diabetic Ketoacidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major diabetic ketoacidosis markets are expected to exhibit a CAGR of 4.38% during 2024-2034.
The diabetic ketoacidosis market has been comprehensively analyzed in IMARC's new report titled "Diabetic Ketoacidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic ketoacidosis refers to a serious and potentially life-threatening complication of diabetes mellitus, primarily affecting individuals with type 1 diabetes. The symptoms of the ailment are high blood sugar levels, excessive thirst, frequent urination, significant dehydration, dry mouth, fruity breath odor, rapid breathing, fatigue, weakness, abdominal pain, nausea, vomiting, etc. Various other signs may include confusion, dizziness, blurred vision, and in severe cases, loss of consciousness. These indications result from the body's attempt to eliminate excess glucose and ketones, leading to metabolic acidosis and electrolyte imbalances. The diagnosis of diabetic ketoacidosis involves a combination of clinical evaluation, blood tests, and laboratory findings. Healthcare providers assess the patient's symptoms and medical history, as well as perform a physical examination. Several blood tests are conducted to measure glucose, ketone, electrolyte, and arterial blood gases. Additionally, urine tests may be done to detect ketones and assess kidney function. The presence of hyperglycemia, ketonemia, metabolic acidosis (low blood pH and low bicarbonate levels), and electrolyte imbalances help confirm the diagnosis of the ailment.
The rising cases of absolute or relative deficiency of insulin in the body, which leads to an imbalance in glucose utilization and the production of ketones, are primarily driving the diabetic ketoacidosis market. Besides this, the increasing prevalence of various associated risk factors, such as urinary tract as well as respiratory infections, physical or emotional stress, usage of certain medications like corticosteroids, etc., is also augmenting the market growth. Furthermore, the widespread adoption of intravenous (IV) fluids, typically isotonic saline or a balanced electrolyte solution, for replacing fluid deficits and maintaining adequate blood volume to support organ function is creating a positive outlook for the market. In addition to this, the escalating utilization of thromboprophylaxis measures, such as subcutaneous low molecular weight heparin or intermittent pneumatic compression devices, to prevent venous thromboembolism is acting as another significant growth-inducing factor. These treatments help reduce the risk of potentially serious complications associated with blood clot formation. Moreover, the emerging popularity of continuous subcutaneous insulin infusion, which allows for precise titration of insulin and close monitoring of blood glucose levels, is expected to drive the diabetic ketoacidosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the diabetic ketoacidosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic ketoacidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic ketoacidosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the diabetic ketoacidosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the diabetic ketoacidosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current diabetic ketoacidosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the diabetic ketoacidosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the diabetic ketoacidosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the diabetic ketoacidosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of diabetic ketoacidosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic ketoacidosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic ketoacidosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with diabetic ketoacidosis across the seven major markets?
What is the size of the diabetic ketoacidosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of diabetic ketoacidosis?
What will be the growth rate of patients across the seven major markets?
Diabetic Ketoacidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for diabetic ketoacidosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic ketoacidosis market?
What are the key regulatory events related to the diabetic ketoacidosis market?
What is the structure of clinical trial landscape by status related to the diabetic ketoacidosis market?
What is the structure of clinical trial landscape by phase related to the diabetic ketoacidosis market?
What is the structure of clinical trial landscape by route of administration related to the diabetic ketoacidosis market?
The diabetic ketoacidosis market has been comprehensively analyzed in IMARC's new report titled "Diabetic Ketoacidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic ketoacidosis refers to a serious and potentially life-threatening complication of diabetes mellitus, primarily affecting individuals with type 1 diabetes. The symptoms of the ailment are high blood sugar levels, excessive thirst, frequent urination, significant dehydration, dry mouth, fruity breath odor, rapid breathing, fatigue, weakness, abdominal pain, nausea, vomiting, etc. Various other signs may include confusion, dizziness, blurred vision, and in severe cases, loss of consciousness. These indications result from the body's attempt to eliminate excess glucose and ketones, leading to metabolic acidosis and electrolyte imbalances. The diagnosis of diabetic ketoacidosis involves a combination of clinical evaluation, blood tests, and laboratory findings. Healthcare providers assess the patient's symptoms and medical history, as well as perform a physical examination. Several blood tests are conducted to measure glucose, ketone, electrolyte, and arterial blood gases. Additionally, urine tests may be done to detect ketones and assess kidney function. The presence of hyperglycemia, ketonemia, metabolic acidosis (low blood pH and low bicarbonate levels), and electrolyte imbalances help confirm the diagnosis of the ailment.
The rising cases of absolute or relative deficiency of insulin in the body, which leads to an imbalance in glucose utilization and the production of ketones, are primarily driving the diabetic ketoacidosis market. Besides this, the increasing prevalence of various associated risk factors, such as urinary tract as well as respiratory infections, physical or emotional stress, usage of certain medications like corticosteroids, etc., is also augmenting the market growth. Furthermore, the widespread adoption of intravenous (IV) fluids, typically isotonic saline or a balanced electrolyte solution, for replacing fluid deficits and maintaining adequate blood volume to support organ function is creating a positive outlook for the market. In addition to this, the escalating utilization of thromboprophylaxis measures, such as subcutaneous low molecular weight heparin or intermittent pneumatic compression devices, to prevent venous thromboembolism is acting as another significant growth-inducing factor. These treatments help reduce the risk of potentially serious complications associated with blood clot formation. Moreover, the emerging popularity of continuous subcutaneous insulin infusion, which allows for precise titration of insulin and close monitoring of blood glucose levels, is expected to drive the diabetic ketoacidosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the diabetic ketoacidosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic ketoacidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic ketoacidosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the diabetic ketoacidosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the diabetic ketoacidosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current diabetic ketoacidosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the diabetic ketoacidosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the diabetic ketoacidosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the diabetic ketoacidosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of diabetic ketoacidosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic ketoacidosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic ketoacidosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with diabetic ketoacidosis across the seven major markets?
What is the size of the diabetic ketoacidosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of diabetic ketoacidosis?
What will be the growth rate of patients across the seven major markets?
Diabetic Ketoacidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for diabetic ketoacidosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic ketoacidosis market?
What are the key regulatory events related to the diabetic ketoacidosis market?
What is the structure of clinical trial landscape by status related to the diabetic ketoacidosis market?
What is the structure of clinical trial landscape by phase related to the diabetic ketoacidosis market?
What is the structure of clinical trial landscape by route of administration related to the diabetic ketoacidosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DIABETIC KETOACIDOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DIABETIC KETOACIDOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DIABETIC KETOACIDOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 DIABETIC KETOACIDOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DIABETIC KETOACIDOSIS - UNMET NEEDS
10 DIABETIC KETOACIDOSIS - KEY ENDPOINTS OF TREATMENT
11 DIABETIC KETOACIDOSIS - MARKETED PRODUCTS
11.1 List of Diabetic Ketoacidosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 DIABETIC KETOACIDOSIS - PIPELINE DRUGS
12.1 List of Diabetic Ketoacidosis Pipeline Drugs Across the Top 7 Markets
12.1.1 PMZ 2123 - Pharmazz
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DIABETIC KETOACIDOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DIABETIC KETOACIDOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DIABETIC KETOACIDOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Diabetic Ketoacidosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Diabetic Ketoacidosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Diabetic Ketoacidosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Diabetic Ketoacidosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Diabetic Ketoacidosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Diabetic Ketoacidosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Diabetic Ketoacidosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Diabetic Ketoacidosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Diabetic Ketoacidosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Diabetic Ketoacidosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Diabetic Ketoacidosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Diabetic Ketoacidosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Diabetic Ketoacidosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Diabetic Ketoacidosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Diabetic Ketoacidosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Diabetic Ketoacidosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
16 DIABETIC KETOACIDOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DIABETIC KETOACIDOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DIABETIC KETOACIDOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DIABETIC KETOACIDOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DIABETIC KETOACIDOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DIABETIC KETOACIDOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 DIABETIC KETOACIDOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DIABETIC KETOACIDOSIS - UNMET NEEDS
10 DIABETIC KETOACIDOSIS - KEY ENDPOINTS OF TREATMENT
11 DIABETIC KETOACIDOSIS - MARKETED PRODUCTS
11.1 List of Diabetic Ketoacidosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 DIABETIC KETOACIDOSIS - PIPELINE DRUGS
12.1 List of Diabetic Ketoacidosis Pipeline Drugs Across the Top 7 Markets
12.1.1 PMZ 2123 - Pharmazz
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DIABETIC KETOACIDOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DIABETIC KETOACIDOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DIABETIC KETOACIDOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Diabetic Ketoacidosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Diabetic Ketoacidosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Diabetic Ketoacidosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Diabetic Ketoacidosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Diabetic Ketoacidosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Diabetic Ketoacidosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Diabetic Ketoacidosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Diabetic Ketoacidosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Diabetic Ketoacidosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Diabetic Ketoacidosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Diabetic Ketoacidosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Diabetic Ketoacidosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Diabetic Ketoacidosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Diabetic Ketoacidosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Diabetic Ketoacidosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Diabetic Ketoacidosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Diabetic Ketoacidosis - Access and Reimbursement Overview
16 DIABETIC KETOACIDOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DIABETIC KETOACIDOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DIABETIC KETOACIDOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
